Current treatment of chronic lymphocytic leukemia. New opportunities and new difficulties
Chronic lymphocytic leukemia (CLL) - the most common subtype of hemoblastoses (22-30%). It can have aggressive or indolent course, with diverse clinical symptoms. The foundation of this diversity is the molecular features of the disease. The incidence of CLL in Russia is 6.67 per 100 000 population....
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2016-12-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/view/27104 |
| id |
doaj-f9d4515d4ab5428f943abf4de3e06d62 |
|---|---|
| record_format |
Article |
| spelling |
doaj-f9d4515d4ab5428f943abf4de3e06d622020-11-25T02:58:05ZrusIP Habib O.N.Современная онкология1815-14341815-14422016-12-01185161924324Current treatment of chronic lymphocytic leukemia. New opportunities and new difficultiesO S Samoylova0N.A.Semashko Nizhny Novgorod Regional Clinical HospitalChronic lymphocytic leukemia (CLL) - the most common subtype of hemoblastoses (22-30%). It can have aggressive or indolent course, with diverse clinical symptoms. The foundation of this diversity is the molecular features of the disease. The incidence of CLL in Russia is 6.67 per 100 000 population. By 2016 several novel therapies for CLL have been registered in Russia, including ibrutinib and obinutuzumab, but the implementation of the novel drugs into daily practice meets certain difficulties. This article describes some of them based on the experience on the N.A.Semashko Nizhny Novgorod regional clinical hospital.https://modernonco.orscience.ru/1815-1434/article/view/27104chronic lymphocytic leukemiaibrutinibobinutuzumab |
| collection |
DOAJ |
| language |
Russian |
| format |
Article |
| sources |
DOAJ |
| author |
O S Samoylova |
| spellingShingle |
O S Samoylova Current treatment of chronic lymphocytic leukemia. New opportunities and new difficulties Современная онкология chronic lymphocytic leukemia ibrutinib obinutuzumab |
| author_facet |
O S Samoylova |
| author_sort |
O S Samoylova |
| title |
Current treatment of chronic lymphocytic leukemia. New opportunities and new difficulties |
| title_short |
Current treatment of chronic lymphocytic leukemia. New opportunities and new difficulties |
| title_full |
Current treatment of chronic lymphocytic leukemia. New opportunities and new difficulties |
| title_fullStr |
Current treatment of chronic lymphocytic leukemia. New opportunities and new difficulties |
| title_full_unstemmed |
Current treatment of chronic lymphocytic leukemia. New opportunities and new difficulties |
| title_sort |
current treatment of chronic lymphocytic leukemia. new opportunities and new difficulties |
| publisher |
IP Habib O.N. |
| series |
Современная онкология |
| issn |
1815-1434 1815-1442 |
| publishDate |
2016-12-01 |
| description |
Chronic lymphocytic leukemia (CLL) - the most common subtype of hemoblastoses (22-30%). It can have aggressive or indolent course, with diverse clinical symptoms. The foundation of this diversity is the molecular features of the disease. The incidence of CLL in Russia is 6.67 per 100 000 population. By 2016 several novel therapies for CLL have been registered in Russia, including ibrutinib and obinutuzumab, but the implementation of the novel drugs into daily practice meets certain difficulties. This article describes some of them based on the experience on the N.A.Semashko Nizhny Novgorod regional clinical hospital. |
| topic |
chronic lymphocytic leukemia ibrutinib obinutuzumab |
| url |
https://modernonco.orscience.ru/1815-1434/article/view/27104 |
| work_keys_str_mv |
AT ossamoylova currenttreatmentofchroniclymphocyticleukemianewopportunitiesandnewdifficulties |
| _version_ |
1724708524155469824 |